We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Diagnostics Showcases Range of Diabetes and Hematology POC Devices

By LabMedica International staff writers
Posted on 01 Aug 2024
Print article
Image: EKF’s cutting-edge point-of-care diagnostic solutions are on display at ADLM 2024 (Photo courtesy of EKF Diagnostics)
Image: EKF’s cutting-edge point-of-care diagnostic solutions are on display at ADLM 2024 (Photo courtesy of EKF Diagnostics)

EKF Diagnostics (Cardiff, Wales, UK) is showcasing its range of diabetes and hematology point-of-care (POC) devices and connectivity software at ADLM 2024.

Among its diabetes POC devices, EKF is highlighting the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c). The semi-automated analyzer has been designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. EKF is also showcasing the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. This fully automated hemoglobin A1c analyzer uses patented boronate affinity fluorescence quenching technology to measure glycated hemoglobin from a 4 μl sample taken from a capillary or venous whole blood. Also featuring at the show is the STAT-Site WB analyzer for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples.

Additionally, EKF is presenting its newly launched Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer. The new and updated analyzer has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the Biosen C-Line to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians. Visitors to the EKF booth at the show can also experience the EKF Link middleware solution for healthcare providers that is designed to manage their POC analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced with most vendors’ POC analyzers to permit the real-time management of data including patient test results, QC results, operator management, and analyzer configuration.

Within its portfolio of hematology POC devices, EKF is highlighting the DiaSpect Tm hand-held hemoglobin analyzer which is now powered by EKF Link, enabling new functions like hematocrit calculation, quality control management, and patient data management functions. The proven technology of DiaSpect Tm delivers laboratory-quality results in one second from the microcuvette being placed into the analyzer. In addition, EKF is featuring the Hemo Control POC hemoglobin analyzer which is designed to provide quantitative, lab-quality hemoglobin results in 25 seconds. Also featuring at the show is the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60-second spin.

Related Links:
EKF Diagnostics

New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
DNA Extraction Kit
Ron’s Gel Extraction Mini Kit
New
Automated Biochemistry Analyzer
AutoChem B861

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.